DEXONE 1.5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXONE 1.5 (DEXONE 1.5).
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by other CYP450 enzymes. |
| Excretion | Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged. |
| Half-life | Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions. |
| Protein binding | Approximately 77% bound, primarily to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.7-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 80-90%; Intramuscular: 100% (relative to IV). |
| Onset of Action | Intravenous: 15-30 minutes; Oral: 1-2 hours; Intramuscular: 30-60 minutes. |
| Duration of Action | Duration of anti-inflammatory effect: 24-48 hours after a single dose, with adrenal suppression lasting up to 72 hours. |
| Molecular Weight | 392.461 |
1.5 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, use 0.75 mg once daily; for GFR <10 mL/min, use 0.5 mg once daily |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 0.75 mg once daily; Child-Pugh C: 0.5 mg once daily |
| Pediatric use | 0.02-0.05 mg/kg orally once daily; maximum 1.5 mg/day |
| Geriatric use | Start at 0.75 mg orally once daily; titrate based on response and tolerance |
| 1st trimester | Category D. Use only if potential benefit justifies risk. Associated with oral clefts at doses >1 mg/day. |
| 2nd trimester | Category D. May cause fetal adrenal suppression. Monitor for intrauterine growth restriction. |
| 3rd trimester | Category D. Risk of neonatal adrenal insufficiency and premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for DEXONE 1.5 (DEXONE 1.5).
| Placental transfer | Dexamethasone crosses the placenta efficiently, with cord blood levels approximately 33% of maternal levels. |
| Breastfeeding | Small amounts excreted into breast milk. At doses >20 mg/day, monitor infant for adrenal suppression. Short-term, low-dose use is generally acceptable. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionKnown hypersensitivity to dexamethasone or any componentAdministration of live or live-attenuated vaccines
| Precautions | Immunosuppression and increased susceptibility to infections, Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use, Adrenal insufficiency upon withdrawal, Gastrointestinal perforation (especially in inflammatory bowel disease), Osteoporosis with long-term use, Cushing's syndrome with high doses, Exacerbation of systemic fungal infections, Live or live-attenuated vaccines contraindicated during immunosuppressive doses, Use caution in patients with hypertension, congestive heart failure, or ocular herpes simplex |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they increase dexamethasone levels. Limit salt and high-sodium foods due to fluid retention risk. Alcohol may increase gastric irritation and should be avoided. Take with a meal to reduce GI upset. |
Loading safety data…
| L3 (Moderately Safe) for short-term use; L4 (Possibly Hazardous) for high-dose or prolonged use. |
| Teratogenic Risk | DEXONE 1.5 (dexamethasone 1.5 mg) is a corticosteroid. First trimester: Increased risk of oral clefts (odds ratio ~3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, and oligohydramnios with prolonged use. Corticosteroids are generally avoided unless maternal benefit outweighs fetal risk. |
| Fetal Monitoring | Monitor maternal blood glucose (corticosteroid-induced hyperglycemia), blood pressure, weight, and edema. Fetal monitoring: serial ultrasound for growth restriction and amniotic fluid volume; consider fetal adrenal suppression if prolonged therapy. |
| Fertility Effects | Dexamethasone may interfere with hypothalamic-pituitary-adrenal axis, potentially causing menstrual irregularities or transient anovulation. In males, no direct effect on spermatogenesis reported at therapeutic doses. |
| Clinical Pearls | Dexone 1.5 (dexamethasone 1.5 mg) is a long-acting glucocorticoid with minimal mineralocorticoid activity. Due to its potency, taper dose slowly to avoid adrenal crisis. Monitor for hyperglycemia, especially in diabetics; consider insulin adjustment. High doses can cause gastric irritation—co-administer with PPI or H2 blocker in at-risk patients. Avoid live vaccines during therapy. For cerebral edema, use higher doses (10-20 mg IV/IM then taper). Check intraocular pressure if prolonged use. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not stop suddenly; follow your doctor's tapering schedule. · Report signs of infection (fever, sore throat) or worsening swelling. · Avoid live vaccines (e.g., MMR, nasal flu) while on this medication. · Monitor blood sugar if diabetic; report high readings to your doctor. · May cause mood swings, insomnia, or increased appetite; notify if severe. · Use sunscreen and protective clothing; this drug increases sun sensitivity. · Carry a medical ID or alert card stating you take corticosteroids. |